Veracyte announces VANDAAM trial data at ASTRO

Veracyte announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings confirm that the genomic test offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions for African American men, a population that is disproportionately impacted by the disease. The new data were shared in an oral presentation at ASTRO 2024, the annual meeting of the American Society for Radiation Oncology, in Washington, D.C. Following standard treatment, patients with high Decipher test scores were eight times more likely to have biochemical recurrence within 2 years, compared to those with lower genomic test scores. When adjusted for other variables, such as age, race, pre-treatment prostate specific antigen, and Gleason score, those patients with high Decipher test scores remained at significantly high risk of rapid-onset BCR. There was no significant difference in the results between African American and non-African American men.